19:54 , Apr 27, 2018 |  BC Week In Review  |  Financial News

Nextech leads Revolution Medicines' $56M series B

Revolution Medicines Inc. (Redwood City, Calif.) raised $56 million in a series B round led by new investor Nextech Invest, with participation by new investors Casdin Capital and Schroder Adveq and existing investors The Column...
13:59 , Apr 24, 2018 |  BC Extra  |  Financial News

Nextech leads Revolution Medicines' $56M series B

Revolution Medicines Inc. (Redwood City, Calif.) raised $56 million in a series B round led by new investor Nextech Invest, with participation by new investors Casdin Capital and Schroder Adveq and existing investors The Column...
16:27 , Feb 7, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Cell culture and mouse studies suggest inhibiting RAF1 could help treat KRAS-driven lung cancer. In tumor cells from two patient-derived xenograft (PDX) mouse models of KRAS-driven lung cancer, shRNA targeting RAF1 encoded in...
22:52 , Jan 5, 2018 |  BC Week In Review  |  Company News

China investment company SARI acquiring majority stake in Nerviano

China investment company SARI will acquire a 90% stake in cancer company Nerviano Medical Sciences s.r.l. (Nerviano, Italy) for about €300 million ($360 million), which includes an equity investment and a debt restructuring. The deal...
23:03 , Dec 29, 2017 |  BC Extra  |  Company News

China's SARI acquiring Nerviano

China investment company SARI will acquire a 90% stake in cancer company Nerviano Medical Sciences s.r.l. (Nerviano, Italy) for about €300 million ($356.3 million), which includes an equity investment and a debt restructuring. The deal...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
20:29 , Sep 15, 2017 |  BC Week In Review  |  Financial News

BridgeBio raises $135M round

On Sept. 13, BridgeBio Pharma (Palo Alto, Calif.) raised $135 million in an undisclosed venture round led by new investor Viking Global Investors and existing investor KKR. New investors AIG, Aisling Capital, Cormorant Capital and Janus...
22:59 , Sep 13, 2017 |  BC Extra  |  Financial News

BridgeBio raises $135M round

BridgeBio Pharma (Palo Alto, Calif.) raised $135 million in an undisclosed venture round led by new investor Viking Global Investors and existing investor KKR. New investors AIG, Aisling Capital, Cormorant Capital and Janus Funds also...
20:43 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer; melanoma Mouse studies suggest combining Mekinist trametinib with MAPK and CRAF inhibitors could help treat BRAF-dependent lung cancer and melanoma. In six PDX mouse models of BRAF-dependent lung cancer and five of BRAF-dependent...
22:23 , Apr 6, 2017 |  BC Innovations  |  Targets & Mechanisms

Competing for growth

With little in the clinical pipeline for achondroplasia beyond BioMarin Pharmaceutical Inc.’s late-stage vosoritide, startups Therachon AG and BioClin Therapeutics Inc. are rethinking how to tackle the disease. By targeting FGFR3 directly, the two companies...